Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma
- PMID: 16321982
- DOI: 10.1074/jbc.M510843200
Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma
Abstract
Here we showed that a naturally occurring ether analog of lysophosphatidic acid, 1-O-octadecenyl-2-hydroxy-sn-glycero-3-phosphate (AGP), is a high affinity partial agonist of the peroxisome proliferator-activated receptor gamma (PPARgamma). Binding studies using the PPARgamma ligand binding domain showed that [32P]AGP and [3H]rosiglitazone (Rosi) both specifically bind to PPARgamma and compete with each other. [32P]AGP bound PPARgamma with an affinity (Kdapp 60 nm) similar to that of Rosi. However, AGP displaced approximately 40% of bound [3H]Rosi even when applied at a 2000-fold excess. Activation of PPARgamma reporter gene expression by AGP and Rosi showed similar potency, yet AGP-mediated activation was approximately 40% that of Rosi. A complex between AGP and PPARgamma was generated using molecular modeling based on a PPARgamma crystal structure. AGP-interacting residues were compared with Rosi-interacting residues identified within the Rosi-PPARgamma co-crystal complex. These comparisons showed that the two ligands occupy partially overlapping positions but make different hydrogen bonding and ion pairing interactions. Site-specific mutants of PPARgamma were prepared to examine individual ligand binding. H323A and H449A mutants showed reduced binding of Rosi but maintained binding of AGP. In contrast, the R288A showed reduced AGP binding but maintained Rosi binding. Finally, alanine replacement of Tyr-473 abolished binding and activation by Rosi and AGP. These observations indicate that the endogenous lipid mediator AGP is a high affinity ligand of PPARgamma but that it binds via interactions distinct from those involved in Rosi binding. These distinct interactions are likely responsible for the partial PPARgamma agonism of AGP.
Similar articles
-
Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR.Cell Signal. 2009 Dec;21(12):1874-84. doi: 10.1016/j.cellsig.2009.08.003. Epub 2009 Aug 23. Cell Signal. 2009. PMID: 19709640 Free PMC article.
-
Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.J Biol Chem. 2010 Apr 16;285(16):12321-33. doi: 10.1074/jbc.M109.091512. Epub 2010 Jan 22. J Biol Chem. 2010. PMID: 20097754 Free PMC article.
-
T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.J Biol Chem. 2008 Apr 4;283(14):9168-76. doi: 10.1074/jbc.M800104200. Epub 2008 Feb 7. J Biol Chem. 2008. PMID: 18263587
-
Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.Trends Pharmacol Sci. 2015 Oct;36(10):688-704. doi: 10.1016/j.tips.2015.06.010. Trends Pharmacol Sci. 2015. PMID: 26435213 Review.
-
New insights into molecular mechanisms of rosiglitazone in monotherapy or combination therapy against cancers.Chem Biol Interact. 2018 Dec 25;296:162-170. doi: 10.1016/j.cbi.2018.09.019. Epub 2018 Sep 29. Chem Biol Interact. 2018. PMID: 30278161 Review.
Cited by
-
Cyclic AMP-stimulated interaction between steroidogenic factor 1 and diacylglycerol kinase theta facilitates induction of CYP17.Mol Cell Biol. 2007 Oct;27(19):6669-85. doi: 10.1128/MCB.00355-07. Epub 2007 Jul 30. Mol Cell Biol. 2007. PMID: 17664281 Free PMC article.
-
Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.Adv Biol Regul. 2019 Jan;71:183-193. doi: 10.1016/j.jbior.2018.09.008. Epub 2018 Sep 16. Adv Biol Regul. 2019. PMID: 30243984 Free PMC article. Review.
-
Lysophospholipid Signaling in the Epithelial Ovarian Cancer Tumor Microenvironment.Cancers (Basel). 2018 Jul 9;10(7):227. doi: 10.3390/cancers10070227. Cancers (Basel). 2018. PMID: 29987226 Free PMC article. Review.
-
Inhibition of the Mitochondrial Pyruvate Carrier by Tolylfluanid.Endocrinology. 2018 Feb 1;159(2):609-621. doi: 10.1210/en.2017-00695. Endocrinology. 2018. PMID: 29126303 Free PMC article.
-
Lysophospholipid interactions with protein targets.Biochim Biophys Acta. 2008 Sep;1781(9):540-6. doi: 10.1016/j.bbalip.2008.04.011. Epub 2008 May 2. Biochim Biophys Acta. 2008. PMID: 18501204 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources